Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading: Results of glucose loading on 2 consecutive days

Diabetes, Obesity and Metabolism

Volumn 7, Issue 2, 2005, Pages 182-188

  Mori, Yutaka ^a   Mamori, S ^a   Tajima, N ^b  

^a National Hospital Organization Utsunomiya National Hospital   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Early insulin secretion; Nateglinide; Obesity; Visceral fat accumulation; Weight loss

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; NATEGLINIDE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HORMONE ACTION; HUMAN; HUMAN EXPERIMENT; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; LIVER; LIVER CLEARANCE; LIVER LEVEL; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PORTAL VEIN BLOOD; SKELETAL MUSCLE; VISCERA; WEIGHT REDUCTION;

EID: 14844346113     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00384.x     Document Type: Article

References (11)

1. Ikenoue T, Akiyosi M, Fujitani S, Okazaki K, Kondo N, Maki T. Hypoglycemic and insulinopenic effects of a novel oral antidiabetic agent, (-) -N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine(A-4166). Br J Pharmacol 1997; 120: 137-145.
2. Ikenoue T, Okazaki K, Fujitani S et al. Effect of a new-hypoglycemic agent, A-4166 [(-)N-(trans-4-Isopropylcyclohexanecarbonyl)- D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull 1997; 20: 354-359.
3. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications, Otsuka Long-Evans Tokushima fatty (OLETF) strain. Diabetes 1992; 41: 1422-1428.
4. Mori Y, Kitahara Y, Miura K, Mine T, Tajima N. Role of early insulin secretion in postglucose-loading hyperglycemia and postfat-loading hyperlipidemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats. Diabetes Obes Metab. (in press).
5. Mori Y, Ishi H, Hikita M, Tajima N. Clinical characteristics of nateglinide response as assessed by insulinogenic indices: preliminary study to determine optimal indication for nateglinide. Adv Ther 2003; 20: 352-355.
6. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
7. Mori Y, Komiya H, Tajima N. Effect of nateglinide on early insulin response after sucrose loading in OLETF rats. Jikeikai Med J 2003; 50: 93-97.
8. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1991; 72: 96-107.
9. Stromblad G, Bjorntorp P. Reduced hepatic insulin clearance in rat with dietary-induced obesity. Metabolism 1986; 35: 323-327.
10. Faber OK, Christensen K, Kehlet H, Madsbad S, Binder C. Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab 1981; 53: 618-621.
11. Mori Y, Kitahara Y, Miura K, Tajima N. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading. Endocrine 2004; 23: 39-44.